Dr. Ives Antonio Valenzuela, MD

Dr. Valenzuela practices at Trustees of Columbia University in the City of New York in Fort Lee, New Jersey.

Dr. Valenzuela's NPI, 1730683954, was assigned on March 21, 2018. Dr. Valenzuela graduated from Vagelos College of Physicians and Surgeons in 2018. Dr. Valenzuela holds New York license 321594-01.

Dr. Valenzuela's primary practice is Trustees of Columbia University in the City of New York, at 400 Kelby St, Fort Lee, NJ 07024 in Bergen County. The practice phone is (646) 317-7111.

Dr. Valenzuela's primary practice is Trustees of Columbia University in the City of New York in Fort Lee, New Jersey. Dr. Valenzuela is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Valenzuela to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Valenzuela practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Valenzuela's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Valenzuela is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Valenzuela's licenses on file in 2 states: New York and Maryland.

Dmand AI lists cataract surgery with lens implant, dry eye, glaucoma, glaucoma surgery, retinal occlusion, secondary membranaous cataract surgery and vision problems among the conditions Dr. Valenzuela treats.

CMS data shows 915 Medicare services from Dr. Valenzuela across 12 procedure codes in 2024, for 295 Medicare patients. Medicare paid $54,968 for them.

CMS counts 295 Medicare patients who saw Dr. Valenzuela in 2024. The largest group is 65 to 74, with 123 patients. 74% of them have high cholesterol, and 72% have high blood pressure. 29% are also on Medicaid. Their average risk score is 1.46, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Valenzuela's median patient age at 63, with 60% women.

In 2024, Dr. Valenzuela wrote 1,421 Medicare Part D claims for 454 patients. 65% of them were for generic drugs. CMS names the drug for 1,326 of them, across 19 drugs with 11 or more claims each, at $131,446 in total drug cost. In 2023, CMS named 2,604 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Valenzuela for performance year 2024, reported through an alternative payment model (APM). Dr. Valenzuela accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 49 procedures of cataract surgery by Dr. Valenzuela, more than 63% of the clinicians it reports for that procedure.

Dmand AI links 10 papers to Dr. Valenzuela, published from 2020 to 2025. 2022 was the busiest year, with 2. The most frequent topics are Intraocular Pressure, Glaucoma and Referral and Consultation. Dr. Valenzuela has published most often in Am J Ophthalmol. Dr. Valenzuela's most frequent co-authors are George A. Cioffi, MD, Jeffrey M. Liebmann, MD and Noga Harizman, MD.

CMS Open Payments shows 21 general payments to Dr. Valenzuela from 5 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 60% of the total. Alcon Laboratories Inc paid the most, $1,528.

Dr. Valenzuela graduated from Vagelos College of Physicians and Surgeons in 2018.

Dr. Valenzuela is in network with 14 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.